Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [525]

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III...

Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma ( Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands )

Comment: Adjuvant ipilimumab in high-risk melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: Immunotherapy combo increases median survival in advanced melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Immunotherapy combo increases median survival in advanced melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Success for ipilimumab and nivolumab combo in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Success for ipilimumab and nivolumab combo in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

T-VEC injections into melanoma lesions show significant response rate

Prof Kevin Harrington - Institute of Cancer Research, London, UK

T-VEC injections into melanoma lesions show significant response rate ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )

Cancer evasion of the immune system: the fundamentals

Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland

Cancer evasion of the immune system: the fundamentals ( Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland )

New antibody-drug conjugate shows early promise against all forms of melanoma

Dr Jeffrey Infante - Tennessee Oncology, Nashville, USA

New antibody-drug conjugate shows early promise against all forms of melanoma ( Dr Jeffrey Infante - Tennessee Oncology, Nashville, USA )

Immunotherapy in melanoma

Dr Adil I. Daud - University of California San Francisco School of Medicine...

Immunotherapy in melanoma ( Dr Adil I. Daud - University of California San Francisco School of Medicine, San Francisco, USA )

Role of AORTIC in dealing with rising cancer rates in Africa

North American Vice president of AORTIC

Role of AORTIC in dealing with rising cancer rates in Africa ( North American Vice president of AORTIC )

Promising advances in the treatment of lung cancer using MK-3475 as an immune...

Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston...

Promising advances in the treatment of lung cancer using MK-3475 as an immune checkpoint inhibitor ( Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA )

More from ecancer